{
      "Rank": 1,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Patients with newly diagnosed extensive cGVHD receive prednisone and cyclosporine or tacrolimus.\n\nPatients with refractory extensive cGVHD receive primary treatment (eg,prednisone and cyclosporine or tacrolimus, or plus mycophenolate mofetil, or methotrexate.)",
            "Patients with newly diagnosed extensive cGVHD receive MSC plus prednisone and cyclosporine or tacrolimus.\n\nPatients with refractory extensive cGVHD receive MSC plus their primary immunosuppressive treatment (eg. prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate.)"
      ],
      "ArmGroupInterventionName": [
            "Drug: Prednisone and cyclosporine or primary therapies",
            "Biological: Mesenchymal stem cell (MSC)"
      ],
      "ArmGroupLabel": [
            "Control group",
            "Mesenchymal stem cell (MSC)"
      ],
      "ArmGroupType": [
            "Active Comparator",
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT00972660"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "Study Design: Treatment, Randomized, Open Label, Parallel Assignment,Safety/Efficacy Study.\n\nThe purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSC) expanded ex-vivo infusion for the treatment of patients who have developed a newly diagnosed extensive or refractory chronic graft versus host disease (chronic GVHD) to the usual therapeutic measures."
      ],
      "BriefTitle": [
            "Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "OTHER"
      ],
      "CollaboratorName": [
            "Sun Yat-sen University"
      ],
      "CompletionDate": [
            "December 2017"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Graft Versus Host Disease"
      ],
      "ConditionAncestorId": [
            "D000007154"
      ],
      "ConditionAncestorTerm": [
            "Immune System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC20",
            "All",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Immune System Diseases",
            "All Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Graft Versus Host Disease",
            "Graft Versus Host Disease",
            "Chronic Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafId": [
            "M8341",
            "M9352",
            "T2832",
            "T1303"
      ],
      "ConditionBrowseLeafName": [
            "Graft vs Host Disease",
            "Immune System Diseases",
            "Homologous Wasting Disease",
            "Chronic Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "high",
            "high"
      ],
      "ConditionMeshId": [
            "D000006086"
      ],
      "ConditionMeshTerm": [
            "Graft vs Host Disease"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "Chronic graft-versus-host disease (GVHD) is one of the main limitations to successful allogeneic hematopoietic stem cell transplantation (HSCT), and has a substantial impact not only on survival but also on the quality of life of otherwise cancer-free patients. Half of the patients undergoing a HLA-identical allografts who survive beyond 100 days may require long-term immunosuppressive treatment for extensive chronic GVHD, often for more than 2 years. More than one-third of patients with chronic GVHD do not respond to first-line therapy, which often involves combinations of corticosteroids and a calcineurin inhibitor. There is no standard second-line or salvage therapy for these patients and they have a poor outcome.\n\nMesenchymal stem cells (MSCs) are multipotent non-hematopoietic stem cells that can differentiate into various lineages and have been used to repair injured tissues. Recently, MSCs have also shown unique immunomodulatory properties ex-vivo, including inhibition of T-cell proliferation after stimulation by allo-antigens and mitogens, and prevention of the activity of cytotoxic T cells.MSCs have been used for the prophylaxis of acute GVHD and for the treatment of patients with steroid-refractory acute GVHD,but rarely have been used for extensive chronic GVHD.\n\nDevelopment of new therapeutic agents and strategies to rescue patients with extensive chronic GVHD would provide a significant benefit in an area of unmet medical need.\n\nIn this study, a single center randomized, non blinded Phase II clinical trial is proposed to study the safety and efficacy of mesenchymal stem cells (MSC) in the management of extensive chronic GVHD newly or refractory to the usual therapeutic measures.\n\nExpanded MSC will be infused at a dose of 2 million cells/kg twice a week for 2 weeks and weekly for the following two weeks (six doses totally)in patients based first-line therapy (steroid plus cyclosporin A ) or their primary immunosuppressive therapies."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nInformed consent obtained from patient and donor.\nAny patient who has undergone allogeneic stem cell transplantation with extensive chronic GVHD.\nHave not received additional agent for cGVHD within 3 months.\nExpected life is more than 90 days.\nAdequate pulmonary function with no evidence of chronic obstructive or severe restrictive pulmonary disease.\nAdequate cardiac function with no evidence of uncontrolled high blood pressure,congestive heart failure, angina pectoris, acute myocardial infarction within 6 months prior to the process.\n\nExclusion Criteria:\n\nInvasive fungal disease.\nActive cytomegalovirus (CMV)/Epstein-Barr virus(EBV)/varicella disease).\nPatient is with a history of hypersensitivity to bovine products.\nRelapsed malignancy."
      ],
      "EnrollmentCount": [
            "52"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000893",
            "D000005938",
            "D000006728",
            "D000006730",
            "D000045505",
            "D000018931",
            "D000000970",
            "D000004791",
            "D000045504",
            "D000007166",
            "D000007155",
            "D000000935",
            "D000000890",
            "D000003879",
            "D000018501",
            "D000065095",
            "D000000903",
            "D000000904",
            "D000000995",
            "D000000900"
      ],
      "InterventionAncestorTerm": [
            "Anti-Inflammatory Agents",
            "Glucocorticoids",
            "Hormones",
            "Hormones, Hormone Substitutes, and Hormone Antagonists",
            "Physiological Effects of Drugs",
            "Antineoplastic Agents, Hormonal",
            "Antineoplastic Agents",
            "Enzyme Inhibitors",
            "Molecular Mechanisms of Pharmacological Action",
            "Immunosuppressive Agents",
            "Immunologic Factors",
            "Antifungal Agents",
            "Anti-Infective Agents",
            "Dermatologic Agents",
            "Antirheumatic Agents",
            "Calcineurin Inhibitors",
            "Antibiotics, Antineoplastic",
            "Antibiotics, Antitubercular",
            "Antitubercular Agents",
            "Anti-Bacterial Agents"
      ],
      "InterventionArmGroupLabel": [
            "Mesenchymal stem cell (MSC)",
            "Control group"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "ARhu",
            "Derm",
            "All",
            "ANeo",
            "Infl",
            "AnEm",
            "NeuroAg",
            "Gast",
            "Repr"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "Antirheumatic Agents",
            "Dermatologic Agents",
            "All Drugs and Chemicals",
            "Antineoplastic Agents",
            "Anti-Inflammatory Agents",
            "Antiemetics",
            "Neuroprotective Agents",
            "Gastrointestinal Agents",
            "Reproductive Control Agents"
      ],
      "InterventionBrowseLeafAsFound": [
            "CGE",
            "CGE",
            "Benefit",
            "Pelvic",
            "Saline"
      ],
      "InterventionBrowseLeafId": [
            "M18113",
            "M5882",
            "M11280",
            "M13272",
            "M1833",
            "M10901",
            "M10902",
            "M229437",
            "M211896",
            "M248768",
            "M18102",
            "M10855",
            "M13273",
            "M9364",
            "M3369",
            "M8199",
            "M8941",
            "M8940",
            "M20119",
            "M9353",
            "M3406",
            "M5404",
            "M10948",
            "M3366",
            "M6226",
            "M19757",
            "M29605",
            "M3374",
            "M3376",
            "M3463"
      ],
      "InterventionBrowseLeafName": [
            "Cyclosporine",
            "Cyclosporins",
            "Mycophenolic Acid",
            "Prednisolone",
            "Methylprednisolone Acetate",
            "Methylprednisolone",
            "Methylprednisolone Hemisuccinate",
            "Prednisolone acetate",
            "Prednisolone hemisuccinate",
            "Prednisolone phosphate",
            "Tacrolimus",
            "Methotrexate",
            "Prednisone",
            "Immunosuppressive Agents",
            "Anti-Inflammatory Agents",
            "Glucocorticoids",
            "Hormones",
            "Hormone Antagonists",
            "Antineoplastic Agents, Hormonal",
            "Immunologic Factors",
            "Antifungal Agents",
            "Clotrimazole",
            "Miconazole",
            "Anti-Infective Agents",
            "Dermatologic Agents",
            "Antirheumatic Agents",
            "Calcineurin Inhibitors",
            "Anti-Bacterial Agents",
            "Antibiotics, Antitubercular",
            "Antitubercular Agents"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "low",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Experimental:Mesenchymal stem cell(MSC). Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2\u00d71,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).\n\nRefractory extensive cGVHD: receive primary treatment (prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate ) and MSC2\u00d71,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).",
            "Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus\n\nPatients with refractory extensive cGVHD: primary treatment (eg.prednisone 1mg/kg + cyclosporine or tacrolimus,or plus mycophenolate mofetil, or methotrexate.)"
      ],
      "InterventionMeshId": [
            "D000016572",
            "D000009173",
            "D000011241",
            "D000003524",
            "D000016559"
      ],
      "InterventionMeshTerm": [
            "Cyclosporine",
            "Mycophenolic Acid",
            "Prednisone",
            "Cyclosporins",
            "Tacrolimus"
      ],
      "InterventionName": [
            "Mesenchymal stem cell (MSC)",
            "Prednisone and cyclosporine or primary therapies"
      ],
      "InterventionOtherName": [
            "Medrol",
            "Sandimmun Neoral",
            "FK506,prograf",
            "Cellcept",
            "MTX",
            "Medral",
            "Sandimmun Neoral",
            "FK506,Prograf",
            "Cellcept,MMF",
            "MTX"
      ],
      "InterventionType": [
            "Biological",
            "Drug"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Mesenchymal stem cell",
            "Efficacy",
            "Safety"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [
            "Enrolling by invitation"
      ],
      "LastUpdatePostDate": [
            "August 26, 2014"
      ],
      "LastUpdatePostDateType": [
            "Estimate"
      ],
      "LastUpdateSubmitDate": [
            "August 25, 2014"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Guangdong Provincial People's Hospital"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Guangzhou"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "China"
      ],
      "LocationFacility": [
            "Guangdong General Hospital"
      ],
      "LocationState": [
            "Guangdong"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "510080"
      ],
      "MaximumAge": [],
      "MinimumAge": [],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Ex-Vivo Cultured Allogenic Mesenchymal Stem Cells For the Treatment of Extensive Chronic Graft Versus Host Disease"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Guangdong Provincial People's Hospital"
      ],
      "OrgStudyId": [
            "GDREC.[2009]008"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Guangdong Provincial People's Hospital"
      ],
      "OverallOfficialName": [
            "Xin Du, MD.PhD."
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Unknown status"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 2015"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [],
      "PrimaryOutcomeMeasure": [
            "The total Response rate defined as patients with complete and partial response."
      ],
      "PrimaryOutcomeTimeFrame": [
            "Within the first 3 months (plus or minus 7 days) after randomization"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [],
      "SecondaryOutcomeMeasure": [
            "Overall Survival",
            "Events Free Survival",
            "The percentage of patients who can taper or discontinue the immunosuppressive agents",
            "Serum cytokine levels and lymphocyte subsets in patients with chronic GVHD"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Randomization until death or two years post last subject last treatment visit (or clinical cutoff)",
            "Randomization until death or two years post last subject last treatment visit (or clinical cutoff)",
            "Randomization untill two years post the last subject last treatment visit (or clinical cutoff)",
            "Achieve best response within the first 3 months after randomization"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "September 2009"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "May 2010"
      ],
      "StdAge": [
            "Child",
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "September 7, 2009"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "September 4, 2009"
      ],
      "StudyFirstSubmitQCDate": [
            "September 4, 2009"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}